



FILE COPY

September 30, 2002

Ms. Roberta Loomar
Andrx Pharmaceuitcals, Inc.
4955 Orange Drive
Fort Lauderdale, Florida 33314

Dear Ms. Loomar:

Your petition requesting the Food and Drug Administration to determine that Andrx Pharmaceuticals, Inc., in its currently pending ANDA 76-159 (glipizide extended release tablets, 10mg.) will not be required to file a new certification or amend its current Paragraph 1 Certification with respect to U.S. Patent No. 6,361,795 was received by this office on 09/27/02. It was assigned docket number 02P-0426/CP 1 and it was filed on 09/30/02. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Gaffe
Dockets Management Branch

02P-0426

ACK 1